Hormone Therapy and Risk for Cancer in BRCA1 Mutation Carriers Hormone Therapy and Risk for Cancer in BRCA1 Mutation Carriers
Dr Andrew Kaunitz discusses the impact of hormone therapy on risk for breast cancer in BRCA carriers undergoing risk-reduction surgery.Medscape Ob/Gyn
Transgender people on hormones, cisgender people should follow same breast cancer screening guidelines
CONCLUSIONS: This article provides reliable estimates on the burden of Italian women with breast cancer who, once tested with multigene testing, could potentially have their treatment changed to hormone therapy only. PMID: 31088341 [PubMed - as supplied by publisher]
A study published in theBMJhas suggested that transgender women are at a greater risk of developing breast cancer after hormone replacement therapy.Daily Mail
In this study, volunteers were provided with dietary guidelines to follow about what to eat. “Until this study, we lacked any data from a prospective randomized control trial, which is the gold standard, for showing that a dietary approach really does reduce the risk of dying from breast cancer,” says Dr. Neil Iyengar, a medical oncologist at Memorial Sloan Kettering Cancer Center, who was not involved in the study. “Many of us who are proponents of considering diet and exercise in the cancer treatment plan are excited by this trial data because it is the first to show in a very robust way that we can imp...
Researchers found that trans women on hormone therapy had a higher breast cancer risk than the general male population but lower than the general female population.
WEDNESDAY, May 15, 2019 -- Transgender women on gender-confirming hormone therapy have increased odds of breast cancer, but the overall risk is low and not as high as it is for the general female population, a new study finds. Trans women are those...
MHT containing natural estrogen and natural progesterone and some progestogens, is an effective treatment and is safer to the breast than high dose (0,625 mg or more) of equine estrogen with MPA. This latter treatment is associated with a higher incidence of breast cancer, in the range of the higher incidence of breast cancer due to drinking two or more alcohol drinks per day or gaining five of or more kilograms of weight. In women, at risk for breast cancer, with menopausal complaints special attention much be made to prescribe breast safe hormonal therapy.
Objective: Menopausal hormone therapy (MHT) can be performed using sequential or continuous combined regimens. Comparing in-vitro the proliferation of breast cancer cells using these different regimens could lead to suggestions if there may be a different risk of breast cancer which until now is not known. In addition, the aim also was to further investigate the importance of PGRMC1 for hormone induced proliferation using T47D breast cancer cells. This cell line recently has been recommended for breast cancer research.
Background: Studies have demonstrated that hormone therapy may increase the risk of breast cancer (BC), and the synthetic progestins may play a critical role in this event. Progesterone receptor membrane component 1 (PGRMC1) plays a major role in the development of BC, especially with hormone therapy using progestins. Nonetheless, the mechanism of progestin-promoted carcinogenesis of human normal breast epithelial cell has not yet been elaborated. Moreover, the deregulation of microRNA-181a (miR-181a) is often associated with BC and miR-181a shows strong anti-BC effect.